Key result
Aspirin provides clear benefits for secondary prevention of cardiovascular events, but its use in primary prevention must be individualized by weighing the modest absolute risk reduction against the increased risk of gastrointestinal bleeding.
Why the study?
What are the risks and benefits of aspirin in preventing cardiovascular events in patients with and without known cardiovascular disease?
What are the risks and benefits of aspirin in preventing cardiovascular events in patients with and without known cardiovascular disease?
This review highlights the need to balance the cardiovascular benefits of aspirin against bleeding risks, particularly in primary prevention for subgroups like diabetics, women, and the elderly.
Answers are grounded in this paper and cite their sources.
Benefit-risk balance of aspirin for primary prevention in diabetes, women, and elderly remains unclear; leaves open individualized decisions.
Aspirin has a well-established role in preventing adverse events in patients with known cardiovascular disease. However, its benefit in patients without a history of cardiovascular disease is not as clear, particularly in people with diabetes, in women, and in the elderly. Recent studies have provided insight into the risks of aspirin use, particularly bleeding, compared with its benefits in these subgroups.
No takes yet. Share an insight, caveat, or question.
Park et al. (2013) conducted a review in Cardiovascular disease. Aspirin vs. Placebo or no aspirin was evaluated. Aspirin provides clear benefits for secondary prevention of cardiovascular events, but its use in primary prevention must be individualized by weighing the modest absolute risk reduction against the increased risk of gastrointestinal bleeding.
Synapse has enriched 10 related papers. Consider them for comparative context: